Professor Gregory Fulcher

Clinical Professor
Medicine, Northern Clinical School

Telephone +61 2 9926 8388
Fax +61 2 9416 7652

Map

Selected grants

2012

  • Efficacy of Activated protein C to treat Diabetic Leg ulcers - a randomised, controlled clinical trial; Jackson C, Fulcher G, Wraight P, March L, Cooper A; National Health and Medical Research Council (NHMRC)/Project Grants.

2011

  • Adolescent Rural Cohort Study Hormones, Health, Education, Environments and Relationships; Steinbeck K, Hawke C, Hazell P, Skinner R, Ivers R, Booy R, Cumming R, Fulcher G; National Health and Medical Research Council (NHMRC)/Project Grants.
  • Diabetes Case Detection through Emergency Department Admissions; Cheung N, Campbell L, Middleton S, Pollock C, Fulcher G, Watt W, McElduff P; National Health and Medical Research Council (NHMRC)/Partnership Projects.

2008

  • Prevention of type 1 diabetes by activated protein C; Jackson C, Xue M, Fulcher G, Harrison L; Juvenile Diabetes Research Foundation/Research Grant.

2007

  • Effect of APC on pancreas; Fulcher G, Jackson C, Xue M; North Sydney Central Coast Area Health Services (NSCCAH)/Research Grant.

Selected publications

Download citations: PDF RTF Endnote

Journals

  • Van Dieren, S., Kengne, A., Chalmers, J., Beulens, J., Davis, T., Fulcher, G., Heller, S., Patel, A., Colagiuri, S., Hamet, P., Neal, B., Woodward, M., Zoungas, S., et al (2014). Intensification of medication and glycaemic control among patients with type 2 diabetes - the ADVANCE trial. Diabetes, Obesity and Metabolism, 16(5), 426-432. [More Information]
  • Bethel, M., Chacra, A., Deedwania, P., Fulcher, G., Holman, R., Jenssen, T., Kahn, S., Levitt, N., McMurray, J., Califf, R., et al (2013). A Novel Risk Classification Paradigm for Patients With Impaired Glucose Tolerance and High Cardiovascular Risk. The American Journal of Cardiology, 112(2), 231-237. [More Information]
  • Hata, J., Arima, H., Zoungas, S., Fulcher, G., Pollock, C., Adams, M., Watson, J., Joshi, R., Kengne, A., Ninomiya, T., Anderson, C., Woodward, M., Patel, A., MacMahon, S., Chalmers, J., Neal, B., et al (2013). Effects of the endpoint adjudication process on the results of a randomised controlled trial: the ADVANCE trial. PLoS One, 8(2), 1-7. [More Information]
  • Whitmont, K., Fulcher, G., Reid, I., Xue, M., McKelvey, K., Xie, Y., Aboud, M., Ward, C., Smith, M., Cooper, A., March, L., Jackson, C. (2013). Low Circulating Protein C Levels Are Associated with Lower Leg Ulcers in Patients with Diabetes. BioMed Research International, 2013, 1-4. [More Information]
  • Alexander, K., Bryant, W., Cohen, N., Craig, M., Forbes, M., Fulcher, G., Greenaway, T., Harrison, N., Holmes-Walker, J., Howard, G., Jenkins, A., et al (2013). Provision of Quality Care for Adults with Type 1 Diabetes Requiring Insulin Pump Therapy (IIPT). Infusystems Asia, 8(1), 1-6.
  • Neal, B., Perkovic, V., de Zeeuw, D., Mahaffey, K., Fulcher, G., Stein, P., Desai, M., Shaw, W., Jiang, J., Vercruysse, F., et al (2013). Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)-A randomized placebo-controlled trial. American Heart Journal, 166(2), 217-223. [More Information]
  • Xue, M., Dervish, S., Harrison, L., Fulcher, G., Jackson, C. (2012). Activated protein C inhibits pancreatic islet inflammation, stimulates T regulatory cells, and prevents diabetes in non-obese diabetic (NOD) mice. Journal of Biological Chemistry, 287(20), 16356-16364. [More Information]
  • Zoungas, S., Chalmers, J., Ninomiya, T., Li, Q., Cooper, M., Colagiuri, S., Fulcher, G., de Galan, B., Harrap, S., Hamet, P., Patel, A., Neal, B., Woodward, M., et al (2012). Association of HbA1c levels with vascular complications and death in patients with type 2 diabetes: evidence of glycaemic thresholds. Diabetologia: clinical and experimental diabetes and metabolism, 55(3), 636-643. [More Information]
  • Glastras, S., Fulcher, G. (2012). Guidelines for the management of gestational diabetes in pregnancy. Clinical Practice, 9(2), 161-170. [More Information]
  • Steinbeck, K., Hazell, P., Cumming, R., Skinner, R., Ivers, R., Booy, R., Fulcher, G., Handelsman, D., Martin, A., Morgan, G., Starling, J., Bauman, A., Rawsthorne, M., Chow, C., Lam, M., Kelly, P., Paxton, K., Hawke, C., et al (2012). The study design and methodology for the ARCHER Study - Adolescent Rural Cohort Study of Hormones, Health, Education, Environments and Relationships. BMC Pediatrics, 12, 1-10. [More Information]
  • Scott, R., Donoghoe, M., Watts, G., O'Brien, R., Pardy, C., Taskinen, M., Davis, T., Colman, P., Manning, P., Fulcher, G., Keech, A. (2011). Impact of metabolic syndrome and its components on cardiovascular disease event rates in 4900 patients with type 2 diabetes assigned to placebo in the FIELD randomised trial. Cardiovascular Diabetology, 10(1), 102-1-102-8. [More Information]
  • Zinman, B., Fulcher, G., Rao, P., Thomas, N., Endahl, L., Johansen, T., Lindh, R., Lewin, A., Rosenstock, J., Pinget, M., et al (2011). Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2 trial. The Lancet, 377(9769), 924-931. [More Information]
  • Holman, R., Haffner, S., McMurray, J., Bethel, M., Holzhauer, B., Hua, T., Belenkov, Y., Boolell, M., Buse, J., Buckley, B., Fulcher, G., et al (2010). Effect of Nateglinide on the Incidence of Diabetes and Cardiovascular Events. New England Journal of Medicine, 362(16), 1463-1476. [More Information]
  • McMurray, J., Holman, R., Haffner, S., Bethel, M., Holzhauer, B., Hua, T., Belenkov, Y., Boolell, M., Buse, J., Buckley, B., Fulcher, G., et al (2010). Effect of Valsartan on the Incidence of Diabetes and Cardiovascular Events. New England Journal of Medicine, 362(16), 1477-1490. [More Information]
  • Fulcher, G., Colagiuri, S., Phillips, P., Prins, J., Sinha, A., Twigg, S., Dalton, B. (2010). Insulin Intensification for People with Type 2 Diabetes: A Practical Approach. The Australasian Medical Journal, 3(12), 808-813.
  • Scott, R., O'Brien, R., Fulcher, G., Pardy, C., D'Emden, M., Boey (Tse), D., Taskinen, M., Ehnholm, C., Keech, A., FIELD study investigators, F. (2009). Effects of Fenofibrate Treatment on Cardiovascular Disease Risk in 9,795 Individuals With Type 2 Diabetes and Various Components of the Metabolic Syndrome: The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetes Care, 32(3), 493-498. [More Information]
  • Tacon, L., Tan, C., Alvarado, R., Gill, A., Sywak, M., Fulcher, G. (2008). Drug-induced thyroiditis and papillary carcinoma in a minocycline-pigmented black thyroid gland. Thyroid, 18(7), 795-797. [More Information]
  • Whitmont, K., Reid, I., Tritton, S., March, L., Xue, M., Lee, M., Fulcher, G., Sambrook, P., Slobedman, E., Cooper, A., Jackson, C. (2008). Treatment of chronic leg ulcers with topical activated protein C. Archives of Dermatology, 144(11), 1479-1483. [More Information]
  • Niblett, S., King, K., Dunstan, H., Clifton-Bligh, P., Hoskin, L., Roberts, T., Fulcher, G., McGregor, N., Dunsmore, J., Butt, H., Klineberg, I., et al (2007). Hematologic and Urinary Excretion Anomalies in Patients with Chronic Fatigue Syndrome. Experimental Biology and Medicine, 232(8), 1041-1049.
  • Sponiar, M., Sharpe, L., Butow, P., Fulcher, G. (2007). Reproductive choices of women with multiple sclerosis. International Journal of MS Care.
  • Chalmers, J., MacMahon, S., Colman, S., Heller, S., Neal, B., Pan, C., Patel, A., Woodward, M., Cooper, M., Adams, M., Fulcher, G., Mitchell, P., Pollock, C., Watson, J., et al (2005). ADVANCE - Action in Diabetes and Vascular Disease: patient recruitment and characteristics of the study population at baseline. Diabetic Medicine, 22(7), 882-888.
  • McAvoy, B., Fulcher, G., Amerena, J., Conner, G., Beltrame, J., Hankey, G., Keech, A., Lloyd, B., Neale, M., Pollock, C., et al (2005). An evidence based clinical aid for cardiovascular disease--what do GPs think? Australian Family Physician, 34(4), 297-298. [More Information]
  • Fulcher, G., Gilbert, R., Yue, D. (2005). Glargine is superior to neutral protamine Hagedorn for improving glycated haemoglobin and fasting blood glucose levels during intensive insulin therapy. Internal Medicine Journal, 35(9), 536-542. [More Information]
  • Xue, M., Thompson, P., Clifton-Bligh, R., Fulcher, G., Gallery, E., Jackson, C. (2005). Leukocyte matrix metalloproteinase-9 is elevated and contributes to lymphocyte activation in type I diabetes. The International Journal of Biochemistry and Cell Biology, 37(11), 2406-2416. [More Information]
  • Thomas, M., MacIsaac, R., Tsalamandris, C., Molyneaux, L., Goubina, I., Fulcher, G., Yue, D., Jerums, G. (2004). Anemia In Patients With Type 1 Diabetes. Journal of Clinical Endocrinology and Metabolism, 89(9), 4359-4363.
  • Chan, S., Nery, L., McElduff, A., Wilmshurst, E., Fulcher, G., Robinson, B., Stiel, J., Gunton, J., Clifton-Bligh, P. (2004). Intravenous Pamidronate In The Treatment And Prevention Of Osteoporosis. Internal Medicine Journal, 34(4), 162-166.
  • Polhill, T., Saad, S., Poronnik, P., Fulcher, G., Pollock, C. (2004). Short-Term Peaks In Glucose Promote Renal Fibrogenesis Independently Of Total Glucose Exposure. American Journal of Physiology: Renal Physiology (Print), 287(2), F268-F273.
  • Thomas, M., MacIsaac, R., Tsalamandris, C., Molyneaux, L., Goubina, I., Fulcher, G., Yue, D., Jerums, G. (2004). The Burden Of Anaemia In Type 2 Diabetes And The Role Of Nephropathy: A Cross-Sectional Audit. Nephrology, Dialysis, Transplantation, 19(7), 1792-1797.
  • Fulcher, G., Amerena, J., Conner, G., Beltrame, J., Hankey, G., Keech, A., Lloyd, B., McAvoy, B., Neale, M., Pollock, C., et al (2003). Prevention of cardiovascular disease: an evidence-based clinical aid. MJA Focus, (21 July 2003), 1-14.
  • Bernard, E., Delbridge, L., Ho, S., Roach, P., Fulcher, G. (2001). Superimposed double parathyroid adenoma on tc-99m mibi imaging the value of oblique images. Clinical Nuclear Medicine, 26, 876-877.
  • Clifton-Bligh, P., Baber, R., Fulcher, G., Nery,, M., Moreton, T. (2001). The effect of isoflavones extracted from red clover (Rimostil) on lipid and bone metabolism. Menopause, 8, 259-265.
  • Hoskin (Wilson), L., Bligh, P., Hansen, R., Fulcher, G., Gates,, F. (2000). Bone Density and Body Composition in Young Women with Chronic Fatigue Syndrome. Annals of the New York Academy of Sciences, 904(1), 625-627.
  • Clifton-Bligh, P., Hoskin (Wilson), L., Fulcher, G. (2000). Chronic fatigue syndrome and the endocrine system. Current Opinion in Endocrinology, Diabetes and Obesity, 7(2), 102-106. [More Information]
  • Gunton, J., McElduff, A., Sulway, M., Stiel, J., Kelso, I., Boyce, S., Fulcher, G., Robinson, B., Clifton-Bligh, P., Wilmshurst, E. (2000). Outcome of pregnancies complicated by pre-gestational diabetes mellitus. American Journal of Obstetrics and Gynecology, 40, 38-43.

2014

  • Van Dieren, S., Kengne, A., Chalmers, J., Beulens, J., Davis, T., Fulcher, G., Heller, S., Patel, A., Colagiuri, S., Hamet, P., Neal, B., Woodward, M., Zoungas, S., et al (2014). Intensification of medication and glycaemic control among patients with type 2 diabetes - the ADVANCE trial. Diabetes, Obesity and Metabolism, 16(5), 426-432. [More Information]

2013

  • Bethel, M., Chacra, A., Deedwania, P., Fulcher, G., Holman, R., Jenssen, T., Kahn, S., Levitt, N., McMurray, J., Califf, R., et al (2013). A Novel Risk Classification Paradigm for Patients With Impaired Glucose Tolerance and High Cardiovascular Risk. The American Journal of Cardiology, 112(2), 231-237. [More Information]
  • Hata, J., Arima, H., Zoungas, S., Fulcher, G., Pollock, C., Adams, M., Watson, J., Joshi, R., Kengne, A., Ninomiya, T., Anderson, C., Woodward, M., Patel, A., MacMahon, S., Chalmers, J., Neal, B., et al (2013). Effects of the endpoint adjudication process on the results of a randomised controlled trial: the ADVANCE trial. PLoS One, 8(2), 1-7. [More Information]
  • Whitmont, K., Fulcher, G., Reid, I., Xue, M., McKelvey, K., Xie, Y., Aboud, M., Ward, C., Smith, M., Cooper, A., March, L., Jackson, C. (2013). Low Circulating Protein C Levels Are Associated with Lower Leg Ulcers in Patients with Diabetes. BioMed Research International, 2013, 1-4. [More Information]
  • Alexander, K., Bryant, W., Cohen, N., Craig, M., Forbes, M., Fulcher, G., Greenaway, T., Harrison, N., Holmes-Walker, J., Howard, G., Jenkins, A., et al (2013). Provision of Quality Care for Adults with Type 1 Diabetes Requiring Insulin Pump Therapy (IIPT). Infusystems Asia, 8(1), 1-6.
  • Neal, B., Perkovic, V., de Zeeuw, D., Mahaffey, K., Fulcher, G., Stein, P., Desai, M., Shaw, W., Jiang, J., Vercruysse, F., et al (2013). Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)-A randomized placebo-controlled trial. American Heart Journal, 166(2), 217-223. [More Information]

2012

  • Xue, M., Dervish, S., Harrison, L., Fulcher, G., Jackson, C. (2012). Activated protein C inhibits pancreatic islet inflammation, stimulates T regulatory cells, and prevents diabetes in non-obese diabetic (NOD) mice. Journal of Biological Chemistry, 287(20), 16356-16364. [More Information]
  • Zoungas, S., Chalmers, J., Ninomiya, T., Li, Q., Cooper, M., Colagiuri, S., Fulcher, G., de Galan, B., Harrap, S., Hamet, P., Patel, A., Neal, B., Woodward, M., et al (2012). Association of HbA1c levels with vascular complications and death in patients with type 2 diabetes: evidence of glycaemic thresholds. Diabetologia: clinical and experimental diabetes and metabolism, 55(3), 636-643. [More Information]
  • Glastras, S., Fulcher, G. (2012). Guidelines for the management of gestational diabetes in pregnancy. Clinical Practice, 9(2), 161-170. [More Information]
  • Steinbeck, K., Hazell, P., Cumming, R., Skinner, R., Ivers, R., Booy, R., Fulcher, G., Handelsman, D., Martin, A., Morgan, G., Starling, J., Bauman, A., Rawsthorne, M., Chow, C., Lam, M., Kelly, P., Paxton, K., Hawke, C., et al (2012). The study design and methodology for the ARCHER Study - Adolescent Rural Cohort Study of Hormones, Health, Education, Environments and Relationships. BMC Pediatrics, 12, 1-10. [More Information]

2011

  • Scott, R., Donoghoe, M., Watts, G., O'Brien, R., Pardy, C., Taskinen, M., Davis, T., Colman, P., Manning, P., Fulcher, G., Keech, A. (2011). Impact of metabolic syndrome and its components on cardiovascular disease event rates in 4900 patients with type 2 diabetes assigned to placebo in the FIELD randomised trial. Cardiovascular Diabetology, 10(1), 102-1-102-8. [More Information]
  • Zinman, B., Fulcher, G., Rao, P., Thomas, N., Endahl, L., Johansen, T., Lindh, R., Lewin, A., Rosenstock, J., Pinget, M., et al (2011). Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2 trial. The Lancet, 377(9769), 924-931. [More Information]

2010

  • Holman, R., Haffner, S., McMurray, J., Bethel, M., Holzhauer, B., Hua, T., Belenkov, Y., Boolell, M., Buse, J., Buckley, B., Fulcher, G., et al (2010). Effect of Nateglinide on the Incidence of Diabetes and Cardiovascular Events. New England Journal of Medicine, 362(16), 1463-1476. [More Information]
  • McMurray, J., Holman, R., Haffner, S., Bethel, M., Holzhauer, B., Hua, T., Belenkov, Y., Boolell, M., Buse, J., Buckley, B., Fulcher, G., et al (2010). Effect of Valsartan on the Incidence of Diabetes and Cardiovascular Events. New England Journal of Medicine, 362(16), 1477-1490. [More Information]
  • Fulcher, G., Colagiuri, S., Phillips, P., Prins, J., Sinha, A., Twigg, S., Dalton, B. (2010). Insulin Intensification for People with Type 2 Diabetes: A Practical Approach. The Australasian Medical Journal, 3(12), 808-813.

2009

  • Scott, R., O'Brien, R., Fulcher, G., Pardy, C., D'Emden, M., Boey (Tse), D., Taskinen, M., Ehnholm, C., Keech, A., FIELD study investigators, F. (2009). Effects of Fenofibrate Treatment on Cardiovascular Disease Risk in 9,795 Individuals With Type 2 Diabetes and Various Components of the Metabolic Syndrome: The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetes Care, 32(3), 493-498. [More Information]

2008

  • Tacon, L., Tan, C., Alvarado, R., Gill, A., Sywak, M., Fulcher, G. (2008). Drug-induced thyroiditis and papillary carcinoma in a minocycline-pigmented black thyroid gland. Thyroid, 18(7), 795-797. [More Information]
  • Whitmont, K., Reid, I., Tritton, S., March, L., Xue, M., Lee, M., Fulcher, G., Sambrook, P., Slobedman, E., Cooper, A., Jackson, C. (2008). Treatment of chronic leg ulcers with topical activated protein C. Archives of Dermatology, 144(11), 1479-1483. [More Information]

2007

  • Niblett, S., King, K., Dunstan, H., Clifton-Bligh, P., Hoskin, L., Roberts, T., Fulcher, G., McGregor, N., Dunsmore, J., Butt, H., Klineberg, I., et al (2007). Hematologic and Urinary Excretion Anomalies in Patients with Chronic Fatigue Syndrome. Experimental Biology and Medicine, 232(8), 1041-1049.
  • Sponiar, M., Sharpe, L., Butow, P., Fulcher, G. (2007). Reproductive choices of women with multiple sclerosis. International Journal of MS Care.

2005

  • Chalmers, J., MacMahon, S., Colman, S., Heller, S., Neal, B., Pan, C., Patel, A., Woodward, M., Cooper, M., Adams, M., Fulcher, G., Mitchell, P., Pollock, C., Watson, J., et al (2005). ADVANCE - Action in Diabetes and Vascular Disease: patient recruitment and characteristics of the study population at baseline. Diabetic Medicine, 22(7), 882-888.
  • McAvoy, B., Fulcher, G., Amerena, J., Conner, G., Beltrame, J., Hankey, G., Keech, A., Lloyd, B., Neale, M., Pollock, C., et al (2005). An evidence based clinical aid for cardiovascular disease--what do GPs think? Australian Family Physician, 34(4), 297-298. [More Information]
  • Fulcher, G., Gilbert, R., Yue, D. (2005). Glargine is superior to neutral protamine Hagedorn for improving glycated haemoglobin and fasting blood glucose levels during intensive insulin therapy. Internal Medicine Journal, 35(9), 536-542. [More Information]
  • Xue, M., Thompson, P., Clifton-Bligh, R., Fulcher, G., Gallery, E., Jackson, C. (2005). Leukocyte matrix metalloproteinase-9 is elevated and contributes to lymphocyte activation in type I diabetes. The International Journal of Biochemistry and Cell Biology, 37(11), 2406-2416. [More Information]

2004

  • Thomas, M., MacIsaac, R., Tsalamandris, C., Molyneaux, L., Goubina, I., Fulcher, G., Yue, D., Jerums, G. (2004). Anemia In Patients With Type 1 Diabetes. Journal of Clinical Endocrinology and Metabolism, 89(9), 4359-4363.
  • Chan, S., Nery, L., McElduff, A., Wilmshurst, E., Fulcher, G., Robinson, B., Stiel, J., Gunton, J., Clifton-Bligh, P. (2004). Intravenous Pamidronate In The Treatment And Prevention Of Osteoporosis. Internal Medicine Journal, 34(4), 162-166.
  • Polhill, T., Saad, S., Poronnik, P., Fulcher, G., Pollock, C. (2004). Short-Term Peaks In Glucose Promote Renal Fibrogenesis Independently Of Total Glucose Exposure. American Journal of Physiology: Renal Physiology (Print), 287(2), F268-F273.
  • Thomas, M., MacIsaac, R., Tsalamandris, C., Molyneaux, L., Goubina, I., Fulcher, G., Yue, D., Jerums, G. (2004). The Burden Of Anaemia In Type 2 Diabetes And The Role Of Nephropathy: A Cross-Sectional Audit. Nephrology, Dialysis, Transplantation, 19(7), 1792-1797.

2003

  • Fulcher, G., Amerena, J., Conner, G., Beltrame, J., Hankey, G., Keech, A., Lloyd, B., McAvoy, B., Neale, M., Pollock, C., et al (2003). Prevention of cardiovascular disease: an evidence-based clinical aid. MJA Focus, (21 July 2003), 1-14.

2001

  • Bernard, E., Delbridge, L., Ho, S., Roach, P., Fulcher, G. (2001). Superimposed double parathyroid adenoma on tc-99m mibi imaging the value of oblique images. Clinical Nuclear Medicine, 26, 876-877.
  • Clifton-Bligh, P., Baber, R., Fulcher, G., Nery,, M., Moreton, T. (2001). The effect of isoflavones extracted from red clover (Rimostil) on lipid and bone metabolism. Menopause, 8, 259-265.

2000

  • Hoskin (Wilson), L., Bligh, P., Hansen, R., Fulcher, G., Gates,, F. (2000). Bone Density and Body Composition in Young Women with Chronic Fatigue Syndrome. Annals of the New York Academy of Sciences, 904(1), 625-627.
  • Clifton-Bligh, P., Hoskin (Wilson), L., Fulcher, G. (2000). Chronic fatigue syndrome and the endocrine system. Current Opinion in Endocrinology, Diabetes and Obesity, 7(2), 102-106. [More Information]
  • Gunton, J., McElduff, A., Sulway, M., Stiel, J., Kelso, I., Boyce, S., Fulcher, G., Robinson, B., Clifton-Bligh, P., Wilmshurst, E. (2000). Outcome of pregnancies complicated by pre-gestational diabetes mellitus. American Journal of Obstetrics and Gynecology, 40, 38-43.

To update your profile click here. For support on your academic profile contact .